0001209191-22-055528.txt : 20221103
0001209191-22-055528.hdr.sgml : 20221103
20221103165300
ACCESSION NUMBER: 0001209191-22-055528
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221101
FILED AS OF DATE: 20221103
DATE AS OF CHANGE: 20221103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ross Thomas M.
CENTRAL INDEX KEY: 0001874572
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40674
FILM NUMBER: 221358837
MAIL ADDRESS:
STREET 1: C/O MAXCYTE, INC.
STREET 2: 22 FIRSTFIELD ROAD, SUITE 110
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MAXCYTE, INC.
CENTRAL INDEX KEY: 0001287098
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 522210438
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 22 FIRSTFIELD ROAD
STREET 2: SUITE 250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 301-517-5556
MAIL ADDRESS:
STREET 1: 22 FIRSTFIELD ROAD
STREET 2: SUITE 250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
FORMER COMPANY:
FORMER CONFORMED NAME: MAXCYTE INC
DATE OF NAME CHANGE: 20040415
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-01
0
0001287098
MAXCYTE, INC.
MXCT
0001874572
Ross Thomas M.
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400
ROCKVILLE
MD
20850
0
1
0
0
EVP, Global Sales & Marketing
Common Stock
2022-11-01
4
M
0
23429
0.84
A
23429
D
Common Stock
2022-11-01
4
S
0
23429
6.94
D
0
D
Common Stock
2022-11-02
4
M
0
4438
0.84
A
4438
D
Common Stock
2022-11-02
4
M
0
1266
1.08
A
5704
D
Common Stock
2022-11-02
4
S
0
5704
6.85
D
0
D
Employee Stock Option (right to buy)
0.84
2022-11-01
4
M
0
23429
0.00
D
2026-01-10
Common Stock
23429
4438
D
Employee Stock Option (right to buy)
0.84
2022-11-02
4
M
0
4438
0.00
D
2026-01-10
Common Stock
4438
0
D
Employee Stock Option (right to buy)
1.08
2022-11-02
4
M
0
1266
0.00
D
2026-06-13
Common Stock
1266
60734
D
The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022.
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.80 to $7.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant.
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.72 to $6.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
This option is fully vested and exercisable.
/s/ Brian F. Leaf, attorney-in-fact
2022-11-03